Hangzhou Aomuo Pharmaceutical

Hangzhou Aomuo Pharmaceutical is a China-based biopharmaceutical company specializing in the research, development, and commercialization of innovative drugs for perioperative medicine, particularly in anesthesia and cardiovascular care. The company gained significant recognition for developing the first domestic generic version of Sugammadex sodium in China, a breakthrough agent for the reversal of neuromuscular blockade. Aomuo's pipeline includes several proprietary candidates, such as AOM001, targeting unmet needs in anesthesia and critical care. With a focus on high-barrier generic drugs and first-in-class innovations, the company operates integrated R&D and manufacturing facilities. Aomuo aims to become a leader in the global perioperative drug market through strategic partnerships and a robust intellectual property portfolio.